聚-4-羟基丁酸酯用于无脱细胞真皮基质的两阶段胸肌前假体乳房重建术中的腔袋控制:4年回顾性研究
本研究回顾性分析单术者4年间105例患者共194侧乳房行即刻两阶段胸肌前假体乳房重建并使用聚-4-羟基丁酸酯(P4HB)补片控制腔袋的经验。P4HB整合率为97%,16侧乳房(8.2%)发生轻微并发症,10.3%的假体需取出,放疗组取出率显著更高(28.6%,P<0.01)。作者认为P4HB在两阶段胸肌前乳房重建中安全有效,包膜挛缩率与已发表的脱细胞真皮基质数据相当或更低,并可显著降低患者和医疗系统成本。
要点
- P4HB补片整合率为97%,16侧乳房(8.2%)发生轻微并发症。
- 10.3%的假体需取出,放疗组取出率28.6%,显著高于非放疗组(P<0.01)。
- 包膜挛缩率和总体外侧移位率均为1.0%,可见波纹征占15.6%。
核心结论
- 作者认为P4HB在两阶段胸肌前乳房重建中安全有效,包膜挛缩率与已发表的ADM数据相当或更低,并可显著降低患者和医疗系统成本。
研究设计与样本
- 回顾性综述,分析单术者(K.M.)4年间(2018年至2022年)连续行即刻两阶段胸肌前假体乳房重建并使用P4HB补片的患者,共105例、194侧乳房。
主要发现
- P4HB补片整合率为97%。
- 16侧乳房(8.2%)发生轻微并发症,10.3%的假体需取出。
- 放疗组假体取出率为28.6%,显著高于非放疗组(P<0.01)。
- 包膜挛缩率和总体外侧移位率均为1.0%,可见波纹征占15.6%。
- 年龄较大、体质指数较高、当前吸烟或乳房切除标本较大的患者更可能需要假体取出。
关键数值与推荐
- P4HB补片整合率97%;轻微并发症16侧乳房(8.2%);假体取出率10.3%;放疗组取出率28.6%(P<0.01);包膜挛缩率1.0%;总体外侧移位率1.0%;可见波纹征15.6%。
- 微笑 Mastopexy 与下外侧切口在包膜挛缩、外侧移位和波纹征方面无显著差异。
- 包膜挛缩、外侧移位或可见波纹征均无显著预测因素。
临床怎么用
- 作者认为P4HB可作为ADM的低成本替代方案用于两阶段胸肌前乳房重建的腔袋控制和假体支撑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Absorbable mesh has been used to mitigate the potential drawbacks of acellular dermal matrix (ADM)-based breast reconstruction. Poly-4-hydroxybutyrate (P4HB) has been demonstrated to be a lower-cost, safe, and effective alternative to ADM in subpectoral breast reconstruction. In this study, the authors used P4HB for pocket control and implant support in immediate two-stage prepectoral breast reconstruction, examining nonintegration, capsular contracture, implant malposition, patient comorbidities, and risk factors. METHODS: A retrospective review of a single surgeon's (K.M.) experience was performed over a 4-year span for patients who had undergone immediate two-stage prepectoral implant-based breast reconstruction with P4HB mesh. Complications (implant loss, rippling, capsular contracture, and malposition) and patient satisfaction were examined. RESULTS: From 2018 to 2022, 105 patients underwent breast reconstruction using P4HB mesh on a total of 194 breasts. P4HB mesh integration was 97%. Sixteen breasts (8.2%) experienced minor complications, and 10.3% of devices required explantation, which was significantly higher in the irradiated group at 28.6% ( P < 0.01). Patients who were older, had a higher body mass index, were active smokers, or had an increased mastectomy specimen size were more likely to undergo explantation. The capsular contracture rate and overall lateral malposition rate were 1.0%. Visible rippling was present in 15.6% of breasts. There was no significant difference between smile mastopexy and inferolateral incision with regard to capsular contracture, lateral malposition, and rippling. Overall, patients demonstrated a high level of satisfaction. There were no significant predictors of capsular contracture, lateral malposition, or visible rippling. CONCLUSIONS: The authors show the safety and efficacy of P4HB in two-stage prepectoral breast reconstruction. There appears to be equal, if not reduced, capsular contracture rates when compared with the published data on ADM. This represents a large cost reduction to both the patient and the health care system. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
引用
- Movassaghi K, Gilson A, Stewart CN, et al. Prepectoral Two-Stage Implant-Based Breast Reconstruction with Poly-4-Hydroxybutyrate for Pocket Control without the Use of Acellular Dermal Matrix: A 4-Year Review. Plast Reconstr Surg. 2023. PMID: 37410610. doi:10.1097/PRS.0000000000010914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。